ESTRO 2022 - Abstract Book

S900

Abstract book

ESTRO 2022

collect data on the use of MR-Linac for RT and patient outcomes. The registry will provide a linked repository of technical and clinical data that will form a platform for prospective studies and technology assessment. Materials and Methods Ethics approval was granted by St Vincent’s Hospital Human Research Ethics Committee. Figure 1 shows the design of the ADAPT-MRL registry. This registry aims to include an estimated 10,000 eligible participants across Australia and other countries over a 7- to 10-year period. Participants will undergo treatment and assessments in accordance with standard practice. Toxicity and survival outcomes will be assessed at baseline, during treatment, and with 3 monthly follow-up until 24 months, patient reported outcome measures will also be collected. Participants with a variety of cancers will be included.

Figure 1: Design of the ADAPT-MRL registry

Results In 2020, the ADAPT-MRL registry was established in coordination with investigators of The MOMENTUM Study [1], another multi-institutional observational registry of MR-Linac treatments, to enable efficient data aggregation and coordinated sub- studies. Since then, 79 patients have consented to participate in the registry and 41 patients have completed 3-month follow-up. Conclusion Data obtained from the ADAPT-MRL registry is expected to provide evidence on the safety and efficacy of the MR-Linac, a new technical innovation in radiation oncology. We expect this registry will generate data that will be used to optimise treatment techniques, MR-Linac software algorithms, evaluate participants’ outcomes and toxicities and to create a repository of adapted plans, anatomical and functional MR sequences linked to participants’ outcomes. [1] Sophie R, Christodouleas JP, Blezer EL, Akhiat H, Brown K, Choudhury A, Eggert D, Erickson BA, Faivre-Finn C, Fuller CD, Goldwein J. The MOMENTUM Study: An international registry for the evidence-based introduction of MR-guided adaptive therapy. Frontiers in Oncology. 2020;10.

PO-1065 STereotactic Arrhythmia Radioablation (STAR) in Europe – Survey Results of the STOPSTORM Consortium

M. Grehn 1 , E. Pruvot 2 , S. Mandija 3 , N. Andratschke 4 , K. Zeppenfeld 5 , S. Blamek 6 , M. Fast 3 , C. Botrugno 7 , O. Blanck 1 , J. Verhoeff 3 1 University Medical Center Schleswig-Holstein, Department of Radiotherapy, Kiel, Germany; 2 Lausanne University Hospital, Heart and Vessel Department, Lausanne, Switzerland; 3 University Medical Center Utrecht, Department of Radiotherapy,